Fate Therapeutics, Inc. (FATE)

NASDAQHealth CareBiotechnologySnapshot 2026-10-23

$2.11+0.96%

Close 2026-10-23 · 1-day change

Investment OutlookAs of Oct 24, 2026

What could strengthen or challenge Fate Therapeutics, Inc.’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

A matching fiscal period and sufficient coverage are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least five analysts and a baseline within three days of the requested lookback.

Measure / period	Management expectations	Analyst expectations
Quarter ending 2026-12-30
Revenue	—	1.12M
EPS	—	-0.285
Annual ending 2026-12-31
Revenue	—	5.59M
EPS	—	-1.065
Annual ending 2027-12-31
Revenue	—	4.63M
EPS	—	-1.051

Management figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Cash runway extended through prudent spending	It is working to extend its cash runway through restructuring.	Intact	Cash runway falls below 12 months	Qualitative condition This condition has no defined numerical measure. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Stable leadership and execution	A supporting condition in Fate Therapeutics, Inc.'s published investment case. The stated target is No further major leadership departures.	Intact	Additional key executive departures occur	0 key departures vs 0 allowed Recent news highlights clinical progress and grants. No reports of key executive departures or leadership instability. Context reviewed through Oct 23, 2026Last status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.
Revenue stabilizes or grows	A primary condition in Fate Therapeutics, Inc.'s published investment case. The stated target is >=0% YoY revenue growth.	Broken	YoY revenue growth falls below -12% in FY27	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Source date unavailableLast status assessment Oct 24, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Stored thesis · Jul 8, 2026. Latest Evidence uses source-matched measurements where available, alongside the last thesis-monitor assessment. Source periods and assessment dates are shown separately. A new measurement does not automatically change the published status or verify an older target.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-1.05

$-1.03 → $-1.05 · observed estimates

FY2027 revenue$0.00B

$0.01B → $0.00B · observed estimates

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-1.03	$5,236,359	8 / 7
2026-07-25	$-1.03	$5,236,359	8 / 7
2026-07-26	$-1.03	$5,236,359	8 / 7
2026-07-27	$-1.03	$5,236,359	8 / 7
2026-07-28	$-0.99	$5,236,360	8 / 11
2026-07-29	$-1.03	$5,236,359	8 / 7
2026-07-30	$-0.99	$5,236,360	8 / 11
2026-07-31	$-0.99	$5,236,360	8 / 11
2026-08-01	$-1.03	$5,236,359	8 / 7
2026-08-02	$-0.99	$5,236,360	8 / 11
2026-08-03	$-0.99	$5,236,360	8 / 11
2026-08-04	$-1.03	$5,236,359	8 / 7
2026-08-05	$-0.99	$5,236,360	8 / 11
2026-08-06	$-0.99	$5,236,360	8 / 11
2026-08-07	$-1.03	$5,236,359	8 / 7
2026-08-08	$-0.99	$5,236,360	8 / 11
2026-08-09	$-0.99	$5,236,360	8 / 11
2026-08-10	$-0.99	$5,236,360	8 / 11
2026-08-11	$-1.03	$5,236,359	8 / 7
2026-08-12	$-0.99	$5,236,360	8 / 11
2026-08-13	$-1.03	$5,236,359	8 / 7
2026-08-14	$-1.03	$5,236,359	8 / 7
2026-08-15	$-1.03	$5,236,359	8 / 7
2026-08-16	$-1.03	$5,236,359	8 / 7
2026-08-17	$-1.03	$5,236,359	8 / 7
2026-08-18	$-1.03	$5,236,359	8 / 7
2026-08-19	$-1.03	$5,236,359	8 / 7
2026-08-20	$-1.01	$4,611,995	8 / 7
2026-08-21	$-1.01	$4,611,995	8 / 7
2026-08-22	$-1.00	$4,766,541	8 / 7
2026-08-23	$-1.00	$4,766,541	8 / 7
2026-08-24	$-1.00	$4,766,541	8 / 7
2026-08-25	$-1.01	$5,226,195	8 / 7
2026-08-26	$-1.01	$5,226,195	8 / 7
2026-08-27	$-1.01	$5,226,195	8 / 7
2026-08-28	$-1.01	$5,226,195	8 / 7
2026-08-29	$-1.01	$5,226,195	8 / 7
2026-08-30	$-1.01	$5,226,195	8 / 7
2026-08-31	$-1.03	$5,125,333	8 / 7
2026-09-01	$-1.03	$5,125,333	8 / 7
2026-09-02	$-1.05	$4,632,800	8 / 7
2026-09-03	$-1.05	$4,632,800	8 / 7
2026-09-04	$-1.05	$4,632,800	8 / 7
2026-09-05	$-1.05	$4,632,800	8 / 7
2026-09-06	$-1.05	$4,632,800	8 / 7
2026-09-07	$-1.05	$4,632,800	8 / 7
2026-09-08	$-1.05	$4,632,800	8 / 7
2026-09-09	$-1.05	$4,632,800	8 / 7
2026-09-10	$-1.05	$4,632,800	8 / 7
2026-09-11	$-1.05	$4,632,800	8 / 7
2026-09-12	$-1.05	$4,632,800	8 / 7
2026-09-13	$-1.05	$4,632,800	8 / 7
2026-09-14	$-1.05	$4,632,800	8 / 7
2026-09-15	$-1.05	$4,632,800	8 / 7
2026-09-16	$-1.05	$4,632,800	7 / 7
2026-09-17	$-1.05	$4,632,800	7 / 7
2026-09-18	$-1.05	$4,632,800	7 / 7
2026-09-19	$-1.05	$4,632,800	7 / 7
2026-09-20	$-1.05	$4,632,800	7 / 7
2026-09-21	$-1.05	$4,632,800	7 / 7
2026-09-22	$-1.05	$4,632,800	7 / 7
2026-09-23	$-1.05	$4,632,800	7 / 7
2026-09-24	$-1.05	$4,632,800	7 / 7
2026-09-25	$-1.05	$4,632,800	7 / 7
2026-09-26	$-1.05	$4,632,800	7 / 7
2026-09-27	$-1.05	$4,632,800	7 / 7
2026-09-28	$-1.05	$4,632,800	7 / 7
2026-09-29	$-1.05	$4,632,800	7 / 7
2026-09-30	$-1.05	$4,632,800	7 / 7
2026-10-01	$-1.05	$4,632,800	7 / 7
2026-10-02	$-1.05	$4,632,800	7 / 7
2026-10-03	$-1.05	$4,632,800	7 / 7
2026-10-04	$-1.05	$4,632,800	7 / 7
2026-10-05	$-1.05	$4,632,800	7 / 7
2026-10-06	$-1.05	$4,632,800	7 / 7
2026-10-07	$-1.05	$4,632,800	7 / 7
2026-10-08	$-1.05	$4,632,800	7 / 7
2026-10-09	$-1.05	$4,632,800	7 / 7
2026-10-10	$-1.05	$4,632,800	7 / 7
2026-10-11	$-1.05	$4,632,800	7 / 7
2026-10-12	$-1.05	$4,632,800	7 / 7
2026-10-13	$-1.05	$4,632,800	7 / 7
2026-10-14	$-1.05	$4,632,800	7 / 7
2026-10-15	$-1.05	$4,632,800	7 / 7
2026-10-16	$-1.05	$4,632,800	7 / 7
2026-10-17	$-1.05	$4,632,800	7 / 7
2026-10-18	$-1.05	$4,632,800	7 / 7
2026-10-19	$-1.05	$4,632,800	7 / 7
2026-10-20	$-1.05	$4,632,800	7 / 7
2026-10-21	$-1.05	$4,632,800	7 / 7
2026-10-22	$-1.05	$4,632,800	7 / 7
2026-10-23	$-1.05	$4,632,800	7 / 7
2026-10-24	$-1.05	$4,632,800	7 / 7

Revenue and EPS estimates track expectations. They are not delivered results or like-for-like proof of a required annual path.

Compare required revenue and earnings

Analyst view

Monthly observations

Buy / Strong BuyHoldSell / Strong Sell

Exact monthly counts

Monthly rating snapshots · fmp. Missing snapshots are not zero.
Date	Buy*	Hold
2026-05-01	6	6
2026-06-01	6	6
2026-07-01	6	6
2026-08-01	6	6
2026-09-01	5	6
2026-10-01	5	6

*Buy includes Strong Buy; Sell includes Strong Sell. Monthly counts describe the analyst mix, not the firms behind each recent action.

Latest: 5 Buy / Strong Buy · 6 Hold · 0 Sell / Strong Sell

0 upgrades0 downgrades0 maintains

Recent actions · Sep 25–Oct 24 · 0 recorded

Price-target changes

30 days

Individual price-target observations are unavailable.

0 raises · 0 cuts · 0 unchanged · 0 without a comparable prior

How this is measured

Sep 25, 2026–Oct 24, 2026. Each firm's latest positive target is paired only with its immediately prior positive target from the same provider, at most 180 days earlier. Unmatched observations have one dot; conflicting observations are not compared.

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Cash runway extended through prudent spendingQualitative condition
Revenue stabilizes or growsPublished status: Broken

Next proof point

Nov 12, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Review earnings

Bottom line

2 of 3 published conditions remain under pressure or need verification. The next results need to address those conditions.

The dated weekly assessment and its assumptions are available in Read detailed Outlook.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.4%Typical daily move · historical

Downside history

-42.4%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

Fate Therapeutics, Inc. outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 24, 2026

What kind of bet this is

This is a speculative clinical-stage biotechnology company, not an established earnings compounder. The multi-year view is in a watch state: several programs have reached clinical milestones, but recent financial performance remains below its industry cohort.

What's priced into Fate Therapeutics, Inc.

The valuation model indicates FATE is expensive versus peers, with some expectations tied to the potential of its pipeline. The model has low confidence, and the evidence does not show that the market is pricing in broad business strength.

What the fundamentals likely do

Near term, the company is likely to remain loss-making as it advances trials and manages expenses. Management has delivered clinical milestones, including the first patient dosed in the Phase 2 lupus nephritis trial and FDA clearance for FT839, while cash and investments declined by $21 million in 2026-Q2.

What Fate Therapeutics, Inc. hinges on

Over the next 1 to 3 years, the thesis hinges on clinical evidence from FT819 and progress with FT839 and FT836, alongside management’s ability to preserve its stated operating runway into 2028. Near-term guidance cuts, a weakening jobs backdrop, and broader healthcare-sector results are also important swing factors.